Trial Outcomes & Findings for A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching (NCT NCT01328262)

NCT ID: NCT01328262

Last Updated: 2025-04-17

Results Overview

The change in hemoglobin concentration after transfusion was recorded. The change is defined as hemoglobin (g/dl) after transfusion minus hemoglobin (g/dl) before transfusion.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

12 participants

Primary outcome timeframe

Measurements of hemoglobin concentration taken from 30 min to 24hours after transfusion (earliest observation recorded)

Results posted on

2025-04-17

Participant Flow

Patients were recruited from November 2010 to January 2011 in the outpatient medical clinic at Haukeland University Hospital

Participant milestones

Participant milestones
Measure
Hemoglobin Dose
Intervention: Calculated red blood cell transfusion Calculated red blood cell transfusion: The subjects receive an amount of red blood cells that has been calculated from their body surface area.
Standard Treatment
Intervention: Standard red blood cell transfusion Standard red blood cell transfusion: The subjects in this group receive the prescribed number of red blood cell units.
Overall Study
STARTED
6
6
Overall Study
COMPLETED
6
6
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Hemoglobin Dose
n=6 Participants
Intervention: Calculated red blood cell transfusion Calculated red blood cell transfusion: The subjects receive an amount of red blood cells that has been calculated from their body surface area.
Standard Treatment
n=6 Participants
Intervention: Standard red blood cell transfusion Standard red blood cell transfusion: The subjects in this group receive the prescribed number of red blood cell units.
Total
n=12 Participants
Total of all reporting groups
Age, Continuous
80 years
n=6 Participants
76 years
n=6 Participants
78 years
n=12 Participants
Sex: Female, Male
Female
1 Participants
n=6 Participants
2 Participants
n=6 Participants
3 Participants
n=12 Participants
Sex: Female, Male
Male
5 Participants
n=6 Participants
4 Participants
n=6 Participants
9 Participants
n=12 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Norway
6 participants
n=6 Participants
6 participants
n=6 Participants
12 participants
n=12 Participants
Body Surface Area
1.81 m^2
n=6 Participants
1.75 m^2
n=6 Participants
1.78 m^2
n=12 Participants
Blood Volume
4.7 liter
n=6 Participants
4.4 liter
n=6 Participants
4.6 liter
n=12 Participants

PRIMARY outcome

Timeframe: Measurements of hemoglobin concentration taken from 30 min to 24hours after transfusion (earliest observation recorded)

The change in hemoglobin concentration after transfusion was recorded. The change is defined as hemoglobin (g/dl) after transfusion minus hemoglobin (g/dl) before transfusion.

Outcome measures

Outcome measures
Measure
Hemoglobin Dose
n=6 Participants
Intervention: Calculated red blood cell transfusion Calculated red blood cell transfusion: The subjects receive an amount of red blood cells with a hemoglobin content that has been calculated from their body surface area.
Standard Treatment
n=6 Participants
Intervention: Standard red blood cell transfusion Standard red blood cell transfusion: The subjects in this group receive the prescribed number of red blood cell units.
Hemoglobin Concentration Change
1.8 g/dl
Interval 1.2 to 2.3
2.0 g/dl
Interval 1.8 to 2.2

Adverse Events

Hemoglobin Dose

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Elin Opheim Netland

Haukeland University Hospital

Phone: +4755976050

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place